Leaderboards/Cancer therapeutics and mechanisms

Cancer therapeutics and mechanisms

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Anna Szymanowska
The University of Texas MD Anderson Cancer Center
2
Meredith S. Eno
Blueprint Medicines (United States)
3
Ana Galán‐Cobo
The University of Texas MD Anderson Cancer Center
4
Kajalben B. Patel
Sardar Vallabhbhai National Institute of Technology Surat
5
Sourav Saha
National Cancer Institute
6
Hazem Ali Mohamed
Zagazig University
7
Alexandria A. Oviatt
Vanderbilt University
8
Mayada I. Shosha
Damietta University
9
Abhishek Ajay
University Hospitals Seidman Cancer Center
10
Mohan Ilakiyalakshmi
Vellore Institute of Technology University

Papers

1
Publication in Cancer Cell (2025) [18 citations, W4412393080]
Cancer Cell|2025
18 cit.
2
Publication in RSC Advances (2024) [8 citations, W4392914431]
RSC Advances|2024
8 cit.
3
Publication in Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2024) [8 citations, W4402709446]
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy|2024
8 cit.
4
The activity of pyrazolo[4,3- <i>e</i> ][1,2,4]triazine and pyrazolo[4,3- <i>e</i> ]tetrazolo[1,5- <i>b</i> ][1,2,4]triazine sulphonamide derivatives in monolayer and spheroid breast cancer cell cultures
Journal of Enzyme Inhibition and Medicinal Chemistry|2024
7 cit.
5
Publication in International Journal of Surgery Case Reports (2024) [W4390848560]
International Journal of Surgery Case Reports|2024
0 cit.
6
Publication in Journal of Fluorescence (2025) [W4409460411]
Journal of Fluorescence|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Bahaa G. M. Youssif
Assiut University
2
Eunyoung Park
University of British Columbia
3
J. Jean Cui
Southern Medical University
4
J. Willem M. Nissink
AstraZeneca (Poland)
5
Peipei Zhang
East China University of Science and Technology
6
Radojka M. Savić
University of California, San Francisco
7
Aaron N. Hata
Harvard University
8
Bree B. Aldridge
Tufts University
9
M.K. Prashanth
Praxis
10
Shengtao Xu
China Pharmaceutical University

Papers

1
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Nature|2023
145 cit.
2
Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation
Angewandte Chemie International Edition|2023
75 cit.
3
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
Nature Cancer|2022
69 cit.
4
Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities
Bioorganic Chemistry|2022
59 cit.
5
New 1,3,4‐oxadiazoles linked with the 1,2,3‐triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase
Archiv der Pharmazie|2022
55 cit.
6
COVID-19-associated monocytic encephalitis (CAME): histological and proteomic evidence from autopsy
Signal Transduction and Targeted Therapy|2023
52 cit.
7
Novel piperine-carboximidamide hybrids: design, synthesis, and antiproliferative activity via a multi-targeted inhibitory pathway
Journal of Enzyme Inhibition and Medicinal Chemistry|2022
48 cit.
8
Design, synthesis, and antiproliferative properties of new 1,2,3-triazole-carboximidamide derivatives as dual EGFR/VEGFR-2 inhibitors
Journal of Molecular Structure|2023
48 cit.
9
Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information
Nucleic Acids Research|2022
47 cit.
10
Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements
Cell Reports Medicine|2022
46 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Yves Pommier
National Cancer Institute
2
Neil Osheroff
Vanderbilt University
3
Jeffrey A. Engelman
Cancer Research Center
4
Anthony Maxwell
John Innes Centre
5
Michael J. Eck
Harvard University
6
James C. Wang
Northwestern University
7
Pasi A. Jänne
Harvard University
8
Mark J. Ratain
University of Chicago
9
Balázs Halmos
Montefiore Medical Center
10
Ira Pastan
National Institutes of Health

Papers

1
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science|2007
4.5k cit.
2
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine|2005
3.9k cit.
3
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine|2011
3.6k cit.
4
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
New England Journal of Medicine|2013
3.4k cit.
5
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Cancer Research|2012
2.2k cit.
6
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
New England Journal of Medicine|2015
2.1k cit.
7
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Proceedings of the National Academy of Sciences|2008
2.1k cit.
8
Expression of a multidrug-resistance gene in human tumors and tissues.
Proceedings of the National Academy of Sciences|1987
1.6k cit.
9
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
New England Journal of Medicine|2014
1.5k cit.
10
Three-dimensional structure of the tyrosine kinase c-Src
Nature|1997
1.4k cit.

Reagents for Cancer therapeutics and mechanisms

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

COL3A1 Antibody

Cited in 9 papers
#30565$317
View Evidence →
Cell Signaling Technology

DTX3L (D5F2J) Rabbit Monoclonal Antibody

Cited in 8 papers
#14795$161,351
View Evidence →
Cell Signaling TechnologyEvidence 69

LAMP1 (D4O1S) Mouse Monoclonal Antibody

Cited in 8 papers
#15665$152,844
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Dystrophin (E4F3S) Rabbit Monoclonal Antibody

Cited in 9 papers
#47759$189,415
View Evidence →
Cell Signaling Technology

CD45RO (UCHL1) Mouse Monoclonal Antibody

Cited in 9 papers
#55618$167,362
View Evidence →
Santa Cruz BiotechnologyEvidence 65

Chk1 (G-4)

Cited in 9 papers
#sc-8408
View Evidence →